Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide-assisted rapid weight loss program for idiopathic intracranial hypertension
2021-006752-14Phase 4Active
- Sponsor
- Rigshospitalet
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in idiopathic intracranial hypertension (IIH) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Intracranial pressure after 8 weeks and Total weight lost. Started Jan 2022; status: active.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on 2021-006752-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006752-14.